T1	Participants 28 55	chemotherapy-induced anemia
T2	Participants 80 120	advanced esophagogastric cancer patients
T3	Participants 516 561	Previously untreated patients were randomized
T4	Participants 928 949	118 patients enrolled
T5	Participants 1580 1626	patients with advanced esophagogastric cancer.
